Definium Therapeutics is trading at $41.01, up 7.34% in pre-market; no confirmed company-specific catalyst was found for September 30.
- Positive Phase 3 Panorama results were announced September 14 and are prior context, not a confirmed overnight trigger.
- Major index gains in the market context were below 0.5%, so broader-market strength does not clearly explain the move.
- Premarket volume information was unavailable.